Infliximab accounts for substantial drug spending in the United States, and dose rounding has become a common practice at many facilities as a way to avoid wasting vials that have only been partially used. However, many institutions do not have standardized approaches to rounding doses, and because infliximab requires a weight-based dose, rounding becomes even more complex.
Infliximab accounts for substantial drug spending in the United States, and dose rounding has become a common practice at many facilities as a way to avoid wasting vials that have only been partially used. However, many institutions do not have standardized approaches to rounding doses, and because infliximab requires a weight-based dose, rounding becomes even more complex.
A research team from the Englewood Hospital and Medical Center in Englewood, New Jersey, recently published a paper on experience in their clinic, where they compared costs among nonstandardized dose-rounding practices, standardized dose-rounding practices, and theoretical exact dosing for infliximab.
Read more about biosimilar infliximab.
The researchers performed a retrospective chart review from October 2016 to March 2017, and included patients receiving infliximab for inflammatory bowel disease in the center’s outpatient infusion clinic. A total of 69 patients received nonstandardized dose rounding, and 45 patients received standardized dose rounding (using a chart with specified measures), during this period.
The nonstandardized group was treated with a total of 773 vials over an approximate 3-month period. Had this group been treated using the standardized dose-rounding chart, the authors estimate that 40 vials of infliximab could have been saved, producing a cost savings of $44,472. If the savings were consistent over a year, assuming that 40 patients receive infliximab each month, using the standardized chart could produce a cost savings of $104,640 per year at the center.
Using standardization in dose rounding led to slightly longer time from weight measurement to order verification, but the minor difference in time was, the investigators said, not practically meaningful. Greater experience with standardized rounding could also reduce the time to order verification.
The authors concluded that dose rounding helped the center to avoid unnecessary costs, and that using a standard method could help to improve pharmacy workflow.
Reference
Park JJ, Boutillier L, Cruz JE, Joung G, Nemeth J. Effect of standardized infliximab dose rounding on an outpatient infusion center. J Manag Care Spec Pharm. 2018;24(10):1028-1033. doi: 10.18553/jmcp.2018.24.10.1028.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Empowering Vulnerable Populations: The Path to Equitable Biologic Therapy Access
December 22nd 2024Elie Bahou, PharmD, senior vice president and system chief pharmacy officer at Providence, discusses strategies to improve equitable access to biologic therapies, including tiered formularies, income-based cost sharing, patient assistance programs, and fostering payer partnerships.
13 Strategies to Avoid the Nocebo Effect During Biosimilar Switching
December 18th 2024A systematic review identified 13 strategies, including patient and provider education, empathetic communication, and shared decision-making, to mitigate the nocebo effect in biosimilar switching, emphasizing the need for a multifaceted approach to improve patient perceptions and therapeutic outcomes.